Clinical Trial Update: BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating BCMA-targeted CAR T cells with or without lenalidomide for multiple myeloma; currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCMA-targeted CAR-T cells
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING